Abeona Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
Expects to submit BLA for EB-101 to FDA in late-2Q/early-3Q 2023 based on positive Phase 3 VIITAL™ study results announced in 4Q 2022 Advancing AAV-based gene therapy... | March 29, 2023
Dmitriy Grachev Amanda Moore Joe Vazzano Madhav Vasanthavada Abeona Therapeutics Inc Head Of Program Leadership
Source: marketscreener.com